Breast Cancer News
In this section, access cutting-edge news about newly diagnosed breast cancer including treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
If you have been diagnosed with HER2 positive, early-stage breast cancer, find out how you and your healthcare team can reduce the risk of heart-damaging side effects potentially caused by some chemotherapy treatments.
CHICAGO (Reuters) - Women who survive breast cancer after undergoing chemotherapy may also have to contend with impairments in attention, memory and planning skills, U.S. researchers said on Monday.
NEW YORK (Reuters Health) - Although fewer and fewer women have died of breast cancer each year over the past two decades, a new study suggests that improvements in survival have been slowest for the oldest women with the disease.
In a five-year review of 20 clinical trials, tamoxifen was shown to safely reduce both 15-year risk for recurrence and death in early-stage estrogen receptor-positive breast cancer.
NEW YORK (Reuters Health) - Breast cancer patients who take antioxidants may have an increased or decreased risk of death or recurrent cancer, depending on which vitamin they use, a new study suggests.
NEW YORK (Reuters Health) - Older women taking the breast cancer drug tamoxifen may have an increased risk of developing diabetes, a new study suggests.
STOCKHOLM (Reuters) - Giving breast cancer patients radiotherapy and chemotherapy at the same time significantly cuts the risk their tumors will come back and should be considered as a new treatment approach across the world, cancer experts said on Sunday.
The first head-to-head comparison of two aromatase inhibitors showed the treatments had similar outcomes in overall survival and recurrence prevention but one had less impact than the other on bone and heart health.
NEW YORK (Reuters Health) - Women newly diagnosed with earlier-stage breast cancer can take a few weeks to prepare for surgery without raising the odds that their tumor will progress, a new study suggests.
LONDON (Reuters) - Breast cancer patients who take the generic drug tamoxifen for five years are less likely to see their cancer return than those who take it for only two years, according to a large long-term study by British scientists.